Caption Management, LLC Avadel Pharmaceuticals PLC Transaction History

Caption Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$12.55 - $17.22 $364,100 - $499,586	-29,012 Reduced 44.56%	36,096 $609,000
Q4 2023 Feb 14, 2024	SELL	$9.64 - $14.59 $154,162 - $233,323	-15,992 Reduced 19.72%	65,108 $919,000
Q3 2023 Nov 14, 2023	BUY	$10.3 - $15.99 $143,242 - $222,372	13,907 Added 20.7%	81,100 $835,000
Q2 2023 Aug 14, 2023	SELL	$8.48 - $16.48 $409,677 - $796,165	-48,311 Reduced 41.83%	67,193 $1.11 Million
Q1 2023 May 15, 2023	BUY	$6.41 - $9.95 $740,380 - $1.15 Million	115,504 New	115,504 $1.06 Million
Q1 2022 May 13, 2022	SELL	$5.46 - $8.29 $1.04 Million - $1.58 Million	-190,000 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$7.34 - $11.18 $293,600 - $447,200	40,000 Added 26.67%	190,000 $1.54 Million
Q3 2021 Nov 12, 2021	BUY	$6.49 - $9.91 $686,693 - $1.05 Million	105,808 Added 239.43%	150,000 $1.47 Million
Q1 2021 May 17, 2021	BUY	$6.61 - $10.07 $292,109 - $445,013	44,192 New	44,192 $400,000
Q4 2020 Feb 16, 2021	SELL	$5.03 - $7.95 $425,538 - $672,570	-84,600 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$5.02 - $8.98 $424,691 - $759,708	84,600 New	84,600 $427,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.